1. Home
  2. RANG vs NTHI Comparison

RANG vs NTHI Comparison

Compare RANG & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RANG
  • NTHI
  • Stock Information
  • Founded
  • RANG 2024
  • NTHI 2008
  • Country
  • RANG United States
  • NTHI United States
  • Employees
  • RANG N/A
  • NTHI N/A
  • Industry
  • RANG
  • NTHI Biotechnology: Pharmaceutical Preparations
  • Sector
  • RANG
  • NTHI Health Care
  • Exchange
  • RANG Nasdaq
  • NTHI Nasdaq
  • Market Cap
  • RANG 165.2M
  • NTHI 142.5M
  • IPO Year
  • RANG 2024
  • NTHI N/A
  • Fundamental
  • Price
  • RANG $10.14
  • NTHI $7.24
  • Analyst Decision
  • RANG
  • NTHI
  • Analyst Count
  • RANG 0
  • NTHI 0
  • Target Price
  • RANG N/A
  • NTHI N/A
  • AVG Volume (30 Days)
  • RANG 5.8K
  • NTHI 108.1K
  • Earning Date
  • RANG 01-01-0001
  • NTHI 01-01-0001
  • Dividend Yield
  • RANG N/A
  • NTHI N/A
  • EPS Growth
  • RANG N/A
  • NTHI N/A
  • EPS
  • RANG N/A
  • NTHI N/A
  • Revenue
  • RANG N/A
  • NTHI $79,990.00
  • Revenue This Year
  • RANG N/A
  • NTHI N/A
  • Revenue Next Year
  • RANG N/A
  • NTHI N/A
  • P/E Ratio
  • RANG N/A
  • NTHI N/A
  • Revenue Growth
  • RANG N/A
  • NTHI 13.52
  • 52 Week Low
  • RANG $9.91
  • NTHI $4.11
  • 52 Week High
  • RANG $10.64
  • NTHI $25.00
  • Technical
  • Relative Strength Index (RSI)
  • RANG N/A
  • NTHI N/A
  • Support Level
  • RANG N/A
  • NTHI N/A
  • Resistance Level
  • RANG N/A
  • NTHI N/A
  • Average True Range (ATR)
  • RANG 0.00
  • NTHI 0.00
  • MACD
  • RANG 0.00
  • NTHI 0.00
  • Stochastic Oscillator
  • RANG 0.00
  • NTHI 0.00

About RANG Range Capital Acquisition Corp. Ordinary Shares

Range Capital Acquisition Corp is a blank check company.

About NTHI NeOnc Technologies Holdings Inc. Common Stock

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").

Share on Social Networks: